Protara Therapeutics (TARA) Other financing activities (2013 - 2026)

Protara Therapeutics' (TARA) quarterly Other financing activities came in at $1.9 million in Q1 2026, up 194100.0% year-on-year from N/an in Q1 2025, and up 9610.0% on a QoQ basis from $20000.0 in Q4 2025.

Protara Therapeutics (TARA) Other financing activities (2013 - 2026) Analysis & Trends

Protara Therapeutics (TARA) has 8 years of Other financing activities data on file, last reported at $1.9 million in Q1 2026.

  • On a quarterly basis, Other financing activities rose 194100.0% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $2.0 million, a 46.64% increase from a year earlier, with the FY2025 full-year figure at $21000.0, down 84.44% from the prior year.
  • Other financing activities for Q1 2026 stood at $1.9 million, up from $20000.0 in the prior quarter.
  • Over the last five years, Other financing activities for TARA reached as high as $1.9 million in Q1 2026 and fell as low as -$7000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Protara Therapeutics 2.25 Mn 2.25 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 1.94 Mn
Mar 31, 2026 1.94 Mn
Dec 31, 2025 20,000.00
Dec 31, 2025 20,000.00
Sep 30, 2025 -7,000.00
Sep 30, 2025 -7,000.00
Jun 30, 2025 7,000.00
Jun 30, 2025 7,000.00
Mar 31, 2025 1,000.00
Mar 31, 2025 1,000.00
Dec 31, 2020 1.34 Mn
Dec 31, 2020 1.34 Mn
Dec 31, 2019 1.00
Dec 31, 2019 1.00
Dec 31, 2017 -1,000.00
Dec 31, 2017 -1,000.00
Jun 30, 2017 1,000.00
Jun 30, 2017 1,000.00
Mar 31, 2017 108,000.00
Mar 31, 2017 108,000.00